亲缘半相合与无关供者造血干细胞移植治疗重型再生障碍性贫血的疗效比较

OBJECTIVE: To evaluate the efficacy of HLA-haploidentical donor hematopoietic transplantation (Haplo-HSCT) for severe aplastic anemia (SAA) by compared with the same period of unrelated donor transplantation (UD-HSCT). METHODS: Of a cohort of 50 SAA patients between September 2012 and July 2014, 26 patients underwent UD-HSCT and 24 patients Haplo-HSCT. RESULTS: OS rate was 91.3% with a median follow-up of 9 (2–26) months. According to transplant type, there was no significant difference between UD- and Haplo-HSCT (96.1% vs 86.0%, P=0.30). 3 of 50 (6%) patients had primary engraft failure. Haplo-HSCT developed higher significantly incidence of Ⅱ–Ⅳ aGVHD (37.5% vs 3.83%, P=0.003) and cGVHD (37.5% vs 15.3%, P=0.030) than UD-HSCT. Haplo-HSCT also had significantly higher incidences of CMV viremia (78.2% vs 46.1%, P=0.005) and EBV viremia (43.1% vs 16.0%, P=0.040), respectively than UD-HSCT. But the incidences of hemorrhagic cystitis were similar between two transplant types (39.1% vs 23.0%, P=0.120). CONCLUSION: This study showed favorable outcome of Haplo-HSCT for SAA, which was comparable with UD-HSCT.